HC Wainwright Issues Positive Forecast for PTGX Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Equities researchers at HC Wainwright raised their Q1 2025 EPS estimates for shares of Protagonist Therapeutics in a research report issued to clients and investors on Monday, February 24th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($0.57) per share for the quarter, up from their previous estimate of ($0.61). HC Wainwright currently has a “Buy” rating and a $54.00 target price on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at $1.00 EPS, FY2025 earnings at ($0.62) EPS, FY2026 earnings at ($1.52) EPS, FY2027 earnings at ($0.39) EPS, FY2028 earnings at $2.83 EPS and FY2029 earnings at $6.91 EPS.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Friday, February 21st. The company reported $1.98 EPS for the quarter, beating the consensus estimate of ($0.09) by $2.07. The business had revenue of $170.64 million during the quarter, compared to analyst estimates of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%.

A number of other equities research analysts have also recently commented on PTGX. StockNews.com cut shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. JPMorgan Chase & Co. upped their price objective on shares of Protagonist Therapeutics from $51.00 to $53.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. The Goldman Sachs Group lowered their price target on Protagonist Therapeutics from $43.00 to $38.00 and set a “neutral” rating on the stock in a research note on Monday. BMO Capital Markets began coverage on shares of Protagonist Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $62.00 price objective for the company. Finally, Wedbush reiterated an “outperform” rating and set a $58.00 price target on shares of Protagonist Therapeutics in a report on Friday, February 21st. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $55.44.

Protagonist Therapeutics Price Performance

Shares of PTGX stock opened at $36.34 on Wednesday. Protagonist Therapeutics has a 1 year low of $24.22 and a 1 year high of $48.89. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of 13.66 and a beta of 2.22. The business has a fifty day moving average of $38.02 and a 200 day moving average of $41.82.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can grew its holdings in Protagonist Therapeutics by 4.5% during the 4th quarter. Bank of Montreal Can now owns 6,250 shares of the company’s stock worth $241,000 after acquiring an additional 270 shares in the last quarter. Maryland State Retirement & Pension System grew its stake in shares of Protagonist Therapeutics by 1.4% in the fourth quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company’s stock worth $779,000 after purchasing an additional 278 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Protagonist Therapeutics by 10.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock valued at $121,000 after buying an additional 295 shares during the period. Louisiana State Employees Retirement System increased its stake in shares of Protagonist Therapeutics by 1.1% during the fourth quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company’s stock valued at $1,112,000 after acquiring an additional 300 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Protagonist Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company’s stock worth $95,000 after buying an additional 379 shares in the last quarter. 98.63% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Protagonist Therapeutics

In other news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $38.18, for a total transaction of $204,606.62. Following the transaction, the chief executive officer now directly owns 540,260 shares in the company, valued at $20,627,126.80. This represents a 0.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.